By Siddhi Mahatole and Sriparna Roy (Reuters) -Charles River Laboratories shares jumped 15% on Wednesday after the company raised its annual profit forecast due to improving demand for contract drug research services. Separately, the Massachusetts-based company also said that it had reached an agreement with activist investor Elliott Management. Charles River's stock climbed to $133.36, though it has fallen approximately 37% year-to-date as the company and other contract drugmakers face sluggish demand among smaller biotech companies, negatively impacting their financial performance. The company raised its 2025 adjusted profit per share forecast to the range of $9.30 to $9.80, up from a previous expectation of $9.10 to $9.60 based on anticipated sales growth in the discovery and safety assessment segment during the first half of the year. On an adjusted basis, it reported quarterly profit of $2.34 per share, beating analysts' average estimate of $2.08 per share, according to data compiled by LSEG. Charles River also said it was launching a strategic review of the business, following a settlement with Elliott Investment, confirming an earlier Reuters report. "We view this strategic action, coupled with a raise in guidance, positively given the political and industry pressures faced by the company in recent quarters," said Mizuho analyst Ann Hynes. Elliott, the largest investor in the contract research firm, prompted the company to initiate a comprehensive business review, exploring various alternatives to enhance long-term stockholder value. Shares of the company have also been affected this year by the U.S. Food and Drug Administration's plans to phase out conventional animal testing for certain drugs. However, Charles River said it does not expect the move to affect earnings in the near term. (Reporting by Siddhi Mahatole and Sriparna Roy in Bengaluru; Editing by Shreya Biswas and Tasim Zahid) View Comments
Charles River raises 2025 profit forecast, reaches deal with activist investor
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...